A new mRNA vaccine developed in Japan has been shown to suppress abnormal blood vessel growth in the retina of mice, offering hope to millions of patients with age-related vision loss.

Neovascularization, a condition that is caused by age-related macular degeneration, is a leading cause of vision loss for people over 60. It affects nearly 200 million people worldwide.

Current treatments require frequent injections directly into the eye. But this vaccine can be delivered intramuscularly — making it less invasive and easier to administer, the Institute of Science Tokyo told NeuroscienceNews.com.

Researchers at the institute were led by Professor Satoshi Uchida of the Department of Advanced Nanomedical Engineering, Science, Tokyo, and Visiting Professor Yasuo Yanagi of the Department of Op

See Full Page